Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147678 | 0.92 | MAPT (0.51) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL10147478 | 0.91 | MAPT (0.53) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL11739144 | 0.87 | MAOB (0.59) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL4947232 | 0.85 | MAOB (0.61) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL10147651 | 0.82 | CYP19A1 (0.53) | MAPTMAOB | |
| SCHEMBL14178921 | 0.82 | MAOB (0.54) | L3MBTL1SMN1; SMN2CA9MAOBCASP3 | |
| SCHEMBL26455213 | 0.82 | MAOB (0.54) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6450060 | 0.81 | MAPT (0.63) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL30789227 | 0.81 | MAOB (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL14616693 | 0.81 | MAOB (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181293-B2 | Method for the synthesis of aspalathin and analogues thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2015-11-10 | — | — | US | disclosed |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2013-01-17 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-7816331-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | PATEL MONA | 2010-03-11 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| US-20060217323-A1 | Substituted indazole-O-glucosides | Tanabe Pharma Corporation (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7084124-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-01 | — | — | US | disclosed |
| EP-1680414-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1572707-B1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1572707-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011592-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | MAPT 4011/4885TDP1 2419/4885L3MBTL1 2740/4885 |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | GYS2, GPR119, UGGT1 | MAPT 4011/4885TDP1 2419/4885L3MBTL1 2740/4885 |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | ASPH, C9, ALDH3A1 | MAPT 3291/4885TDP1 2885/4885L3MBTL1 2398/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | MAPT 3768/4885TDP1 3772/4885L3MBTL1 4769/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | MAPT 1151/4885TDP1 4561/4885L3MBTL1 4033/4885 |
| US-20060217323-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | MAPT 4011/4885TDP1 2419/4885L3MBTL1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.